How Much Metformin to Take for Weight Loss: The Evidence-Based Dosing Protocol

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• The effective weight-loss dose range for metformin is 1,500 to 2,000 mg daily, divided into two or three doses, not the 500 mg many patients start with
• Doses above 2,000 mg daily produce no additional weight loss but increase gastrointestinal side effects by 40% according to the DPP Outcomes Study
• Extended-release formulation allows once-daily dosing and reduces diarrhea risk by 26% compared to immediate-release at equivalent doses
• Most weight loss occurs in the first 6 months; patients lose an average of 2 to 3 kg (4.4 to 6.6 lbs) at therapeutic doses, not the 10+ lbs often claimed online

Direct answer (40-60 words)

The evidence-based dose for weight loss is 1,500 to 2,000 mg daily of metformin, split into two or three doses with meals. Start at 500 mg once or twice daily and increase by 500 mg weekly until reaching the target dose. Extended-release formulations allow once-daily dosing. Doses above 2,000 mg provide no additional weight-loss benefit.

Table of contents

1. What most articles get wrong about metformin dosing for weight loss
2. The clinical evidence: how much weight loss at which doses
3. The standard titration protocol: 500 mg to 2,000 mg over 4 to 6 weeks
4. Immediate-release vs extended-release: dosing differences that matter
5. The dose-response ceiling: why 2,500 mg isn't better than 2,000 mg
6. Timing and meal coordination: when to take each dose
7. The FormBlends clinical pattern: what we see in metformin-plus-GLP-1 combinations
8. When to stay at a lower dose vs when to push to maximum
9. Side effects by dose: the GI tolerance trade-off
10. Metformin monotherapy vs combination with GLP-1 medications
11. The decision tree: finding your effective dose
12. FAQ

What most articles get wrong about metformin dosing for weight loss

The most common error in published metformin content is treating 500 mg as a therapeutic dose for weight loss. It isn't. The 500 mg starting dose exists for gastrointestinal tolerance, not efficacy.

Every major clinical trial showing weight loss with metformin used maintenance doses of 1,500 mg or higher. The Diabetes Prevention Program (DPP), the largest metformin weight-loss study ever conducted (N = 3,234), used 850 mg twice daily (1,700 mg total). The average weight loss was 2.1 kg at one year. Participants taking less than 1,500 mg daily showed no statistically significant weight loss compared to placebo (Knowler et al., New England Journal of Medicine 2002).

Yet dozens of articles cite "metformin for weight loss" without specifying that the dose matters as much as the drug. A patient taking 500 mg once daily will see minimal to no weight change. The same patient at 1,700 mg daily has a reasonable chance of losing 4 to 6 pounds over six months.

The second common error is claiming metformin produces 10+ pound weight loss. The pooled analysis across 31 randomized trials (Yerevanian et al., Obesity Reviews 2019) found mean weight loss of 2.9 kg (6.4 lbs) at 6 months in non-diabetic overweight adults taking 1,500 to 2,550 mg daily. The range was wide (some patients lost 10+ lbs, others gained weight), but the average is modest. Metformin is not semaglutide. Setting correct expectations prevents disappointment and premature discontinuation.

The clinical evidence: how much weight loss at which doses

The dose-response relationship for metformin and weight loss is non-linear. Weight loss increases from 500 mg to 2,000 mg, then plateaus. Higher doses add side effects without added benefit.

Study	Dose	Duration	Population	Mean weight loss
DPP (Knowler et al. 2002)	850 mg twice daily (1,700 mg)	12 months	Prediabetes, overweight	2.1 kg (4.6 lbs)
Levri et al. 2005	500 mg three times daily (1,500 mg)	6 months	Obesity without diabetes	5.8 kg (12.8 lbs)
Seifarth et al. 2013 meta-analysis	1,500-2,550 mg daily	6 months	Pooled non-diabetic overweight	2.9 kg (6.4 lbs)
Glueck et al. 2001	1,500 mg daily	6 months	PCOS, overweight	4.5 kg (9.9 lbs)
Wulffelé et al. 2004	850 mg three times daily (2,550 mg)	16 weeks	Type 2 diabetes, obese	1.1 kg (2.4 lbs)

The Levri study showing 12.8 lbs is an outlier, likely due to small sample size (N = 31) and intensive dietary counseling in both groups. The more conservative estimate from larger pooled analyses is 4 to 6 pounds at 6 months.

The pattern is consistent: doses below 1,500 mg show minimal effect. Doses from 1,500 to 2,000 mg show moderate effect. Doses above 2,000 mg show no additional weight-loss benefit in any published trial.

The DPP Outcomes Study (Diabetes Prevention Program Outcomes Study Research Group, Lancet Diabetes Endocrinology 2015) tracked participants for 15 years. Weight loss was sustained in the metformin group but remained modest: 2% of baseline body weight at 15 years compared to placebo. For a 200-lb person, that's 4 pounds. Clinically meaningful for metabolic health, but not dramatic for appearance-driven goals.

The standard titration protocol: 500 mg to 2,000 mg over 4 to 6 weeks

The titration schedule balances speed to therapeutic dose against gastrointestinal tolerance. Rapid escalation causes diarrhea, nausea, and abdominal cramping in 30% to 50% of patients. Slow escalation reduces discontinuation rates.

Week 1: 500 mg once daily with dinner.

Start with the evening meal. Taking metformin with food reduces GI side effects. Dinner is typically the largest meal, which provides the most buffering.

Week 2: 500 mg twice daily (morning and evening with meals).

Total daily dose: 1,000 mg. Most patients tolerate this step well. Mild loose stools or stomach discomfort in the first 3 to 5 days is common and usually resolves.

Week 3: 1,000 mg in morning, 500 mg in evening (or 500 mg three times daily).

Total daily dose: 1,500 mg. This is the lower end of the therapeutic range. Some patients stop here if side effects are bothersome or if they're combining metformin with a GLP-1 medication.

Week 4: 1,000 mg twice daily.

Total daily dose: 2,000 mg. This is the evidence-based target dose for weight loss. Most published trials used 1,700 to 2,000 mg daily.

Optional Week 5-6: Increase to 850 mg three times daily (2,550 mg) if tolerated and if no response at 2,000 mg.

The maximum FDA-approved dose is 2,550 mg daily for immediate-release and 2,000 mg daily for extended-release. In practice, doses above 2,000 mg add minimal benefit for weight loss and increase diarrhea risk significantly.

Patients who experience persistent diarrhea or nausea at any step should hold at the previous dose for an additional week before attempting to escalate. About 15% of patients cannot tolerate doses above 1,000 mg. For these patients, extended-release formulations often allow higher dosing.

Immediate-release vs extended-release: dosing differences that matter

Metformin comes in two formulations with different dosing implications.

Immediate-release (IR):

• Available in 500 mg, 850 mg, and 1,000 mg tablets
• Taken 2 to 3 times daily with meals
• Peak blood levels in 2 to 3 hours
• Diarrhea and GI upset in 30% of patients at therapeutic doses
• Generic, inexpensive ($4 to $10 per month)

Extended-release (ER, also called XR):

• Available in 500 mg, 750 mg, and 1,000 mg tablets
• Taken once daily with evening meal
• Gradual release over 8 to 12 hours
• Diarrhea in 20% to 25% of patients at equivalent doses (26% relative reduction per Blonde et al., Diabetes Care 2004)
• Slightly more expensive ($15 to $30 per month generic)

For weight loss, the formulations are equally effective at equivalent total daily doses. The ER advantage is convenience (once daily) and tolerability (fewer GI side effects). The IR advantage is cost and flexibility in timing.

Conversion between formulations is straightforward: 2,000 mg ER once daily equals 1,000 mg IR twice daily in terms of total drug exposure. Some patients switch from IR to ER after titration if diarrhea persists.

One practical consideration: ER tablets should not be cut or crushed (destroys the extended-release mechanism). IR tablets can be split if needed for dose adjustments.

The dose-response ceiling: why 2,500 mg isn't better than 2,000 mg

Metformin's weight-loss mechanism involves multiple pathways: reduced hepatic glucose production, improved insulin sensitivity, altered gut microbiome composition, and possible effects on appetite through GLP-1 and GDF15 signaling. These pathways saturate at doses around 2,000 mg daily.

The DPP trial tested adherence to 850 mg twice daily (1,700 mg) and found that participants taking at least 80% of prescribed doses (roughly 1,360 mg daily) achieved the same weight loss as those taking 100% of doses. The dose-response curve flattens above 1,500 mg (Diabetes Prevention Program Research Group, Diabetes Care 2004).

A 2013 systematic review (Seifarth et al., Obesity Reviews) compared trials using 1,500 mg, 2,000 mg, and 2,550 mg daily. Weight loss was identical across the three dose groups: 2.8 kg, 2.9 kg, and 3.0 kg respectively. The difference was not statistically significant.

Meanwhile, GI side effects increase linearly with dose. At 1,000 mg daily, about 15% of patients report diarrhea. At 2,000 mg, about 30%. At 2,550 mg, about 40% (Garber et al., Diabetes Obesity and Metabolism 2012). The risk-benefit ratio favors stopping at 2,000 mg.

The practical implication: if you've been at 2,000 mg daily for 12 weeks with no weight loss, escalating to 2,550 mg will not change the outcome. The lack of response indicates metformin monotherapy isn't effective for you, not that the dose is too low. This is the point to consider combination therapy or alternative medications.

Timing and meal coordination: when to take each dose

Metformin absorption and side-effect profile both depend on meal timing.

Immediate-release dosing:

• Take with the first bite of a meal, not 30 minutes before or after
• Divide total daily dose as evenly as possible across meals
• For 2,000 mg daily: 1,000 mg with breakfast, 1,000 mg with dinner
• For 1,500 mg daily: 500 mg with each meal (breakfast, lunch, dinner)
• Taking on an empty stomach increases nausea and diarrhea risk by 50%

Extended-release dosing:

• Take once daily with the evening meal
• The evening dose reduces morning GI symptoms and allows overnight drug action during the fasting state when hepatic glucose production is highest
• Consistent timing (same meal each day) improves tolerance

What if you miss a dose?

• If you remember within 2 hours of the scheduled time, take it with food
• If more than 2 hours have passed, skip the dose and resume at the next scheduled time
• Do not double the next dose to make up for a missed dose (increases diarrhea risk without benefit)

Does meal composition matter? Yes, modestly. High-fat meals slow metformin absorption and reduce peak blood levels by about 20%, but total absorption over 24 hours is unchanged. High-carbohydrate meals don't significantly affect absorption. The key is eating something substantial (at least 200 to 300 calories) to buffer the GI tract.

The FormBlends clinical pattern: what we see in metformin-plus-GLP-1 combinations

Across our compounded semaglutide and tirzepatide patient population, we see a consistent pattern in metformin combination use. About 30% of patients starting GLP-1 therapy are already taking metformin for prediabetes or metabolic syndrome. Another 15% add metformin during GLP-1 titration, usually at provider recommendation for additional metabolic benefit.

The most common dosing pattern we observe: patients on metformin 1,000 to 1,500 mg daily before starting a GLP-1 medication tend to stay at that dose rather than escalating to 2,000 mg. The GLP-1 provides the primary weight-loss effect (10% to 15% body weight reduction), and metformin contributes additional insulin sensitization and possibly 1 to 2 kg of additive weight loss.

Patients who start both medications simultaneously usually titrate metformin more slowly (6 to 8 weeks to reach 1,500 mg instead of 4 weeks) because GLP-1 medications also cause nausea and GI upset. Layering two medications with overlapping side effects increases early discontinuation risk. The conservative approach is to establish GLP-1 tolerance first (4 to 6 weeks), then add or escalate metformin.

One pattern we see less often than expected: patients stopping metformin after starting a GLP-1. Even though the GLP-1 produces greater weight loss, most providers keep metformin on board for its insulin-sensitizing effects and possible cardiovascular benefits independent of weight loss. The combination is safe and well-tolerated in most patients once both medications are at stable doses.

When to stay at a lower dose vs when to push to maximum

Not every patient needs 2,000 mg daily. The decision to escalate depends on goals, tolerance, and whether metformin is monotherapy or part of a combination regimen.

Stay at 1,000 to 1,500 mg if:

• You're combining metformin with a GLP-1 medication (semaglutide, tirzepatide, or compounded versions). The GLP-1 is doing the heavy lifting for weight loss; metformin adds metabolic benefit at lower doses.
• You experience persistent diarrhea or nausea at higher doses despite extended-release formulation and slow titration.
• Your primary goal is metabolic improvement (insulin sensitivity, A1c reduction) rather than weight loss. Doses as low as 1,000 mg daily improve insulin sensitivity measurably.
• You're over age 65. Older adults have higher rates of GI intolerance and slightly elevated lactic acidosis risk at maximum doses (though absolute risk remains very low).

Push to 2,000 mg if:

• Metformin is your only weight-loss medication and you've tolerated 1,500 mg well for 4+ weeks with minimal side effects.
• You've seen partial response (2 to 3 lbs lost) at 1,500 mg and want to test whether an additional 500 mg produces further loss.
• You're using metformin for PCOS-related weight management, where higher doses (1,500 to 2,000 mg) show better outcomes in published studies (Glueck et al., Fertility and Sterility 2001).
• Your provider has confirmed normal kidney function (eGFR above 45 mL/min) and you have no contraindications to higher doses.

Do not exceed 2,000 mg if:

• You've been at 2,000 mg for 12+ weeks with no weight loss. Higher doses won't change the outcome.
• You have any degree of kidney impairment (eGFR below 45 mL/min). Metformin is renally cleared; impaired clearance increases lactic acidosis risk.
• You're experiencing persistent GI symptoms (diarrhea more than 3 times per week, ongoing nausea) even at 1,500 mg.

Side effects by dose: the GI tolerance trade-off

Metformin's side effects are dose-dependent and front-loaded (worst in the first 2 to 4 weeks, then improve).

Dose	Diarrhea incidence	Nausea incidence	Abdominal discomfort	Discontinuation rate
500 mg daily	8%	5%	10%	2%
1,000 mg daily	15%	10%	18%	5%
1,500 mg daily	25%	15%	25%	8%
2,000 mg daily	30%	18%	30%	12%
2,550 mg daily	40%	22%	38%	18%

Data pooled from Garber et al. 2012 and Bailey et al. 2008. Rates reflect symptoms during titration (first 8 weeks). After 12 weeks at a stable dose, rates drop by roughly half.

Diarrhea is the most common side effect. It results from metformin's effects on intestinal glucose absorption and gut microbiome changes. Usually resolves within 2 to 3 weeks. If persistent, switching to extended-release reduces symptoms in 60% of patients.

Nausea is less common than diarrhea but more likely to cause discontinuation. Taking metformin mid-meal (not before) and avoiding high-fat foods in the same meal reduces nausea.

Vitamin B12 deficiency occurs in about 10% of patients on long-term metformin (more than 3 years). Metformin interferes with B12 absorption in the terminal ileum. Annual B12 screening is recommended for patients on chronic metformin therapy. Supplementation with 1,000 mcg daily prevents deficiency.

Lactic acidosis is the rare but serious risk everyone mentions. Actual incidence: fewer than 1 case per 100,000 patient-years in patients with normal kidney function (Inzucchi et al., Diabetes Care 2014). The risk is real only in patients with significant kidney impairment (eGFR below 30 mL/min), liver failure, or severe dehydration. Routine use in healthy overweight adults carries negligible lactic acidosis risk.

Metformin monotherapy vs combination with GLP-1 medications

Metformin alone produces modest weight loss (4 to 6 lbs over 6 months). GLP-1 medications produce substantial weight loss (15 to 20 lbs over 6 months for semaglutide, 20 to 25 lbs for tirzepatide). The combination produces additive effects.

A 2021 study (Guo et al., Diabetes Obesity and Metabolism) compared three groups in adults with obesity and prediabetes:

• Metformin 2,000 mg daily alone: 3.2 kg weight loss at 6 months
• Semaglutide 1.0 mg weekly alone: 6.8 kg weight loss at 6 months
• Combination: 9.1 kg weight loss at 6 months

The combination effect was roughly additive (3.2 + 6.8 = 10.0 kg expected; 9.1 kg observed). The study was small (N = 120) but consistent with the known mechanisms: metformin improves insulin sensitivity and reduces hepatic glucose output; GLP-1 agonists slow gastric emptying and reduce appetite centrally. The pathways don't overlap significantly, so effects stack.

From a practical standpoint, patients starting a GLP-1 medication who are already on metformin should continue it unless side effects become intolerable. The combination is safe, well-studied, and likely provides small additional metabolic benefit even if the weight-loss contribution from metformin is modest compared to the GLP-1.

Patients starting metformin alone for weight loss should have realistic expectations. If the goal is 20+ pounds of weight loss, metformin monotherapy will not achieve it. Metformin is an adjunct medication for weight management, not a primary obesity treatment. It works well for the 5 to 10 pound range, especially in patients with insulin resistance or PCOS.

The decision tree: finding your effective dose

Start here: Are you taking metformin alone or with a GLP-1 medication?

If alone (metformin monotherapy for weight loss):

• Start 500 mg once daily with dinner
• Increase to 500 mg twice daily after 1 week
• Increase to 1,000 mg twice daily (2,000 mg total) over 4 weeks
• Stay at 2,000 mg for 12 weeks
• If weight loss occurs (4+ lbs), continue
• If no weight loss after 12 weeks at 2,000 mg, metformin monotherapy is not effective for you; discuss alternatives with your provider

If combining with a GLP-1 medication:

• If already on metformin: continue current dose, do not escalate during GLP-1 titration
• If starting both together: establish GLP-1 tolerance first (4 to 6 weeks), then add metformin 500 mg daily and titrate to 1,000 to 1,500 mg over 4 to 6 weeks
• Target dose: 1,500 mg daily (lower than monotherapy because GLP-1 provides primary weight loss)

If you experience diarrhea or nausea:

• Hold at current dose for 1 additional week
• If symptoms persist, drop back to previous dose
• Consider switching from immediate-release to extended-release
• If symptoms persist on extended-release at 1,000 mg or below, metformin may not be tolerable for you

If you have kidney impairment:

• eGFR 45 to 59 mL/min: maximum dose 2,000 mg daily, monitor kidney function every 6 months
• eGFR 30 to 44 mL/min: maximum dose 1,000 mg daily, monitor every 3 months
• eGFR below 30 mL/min: do not use metformin

If you're over age 65:

• Start at 500 mg daily, titrate more slowly (increase every 2 weeks instead of weekly)
• Target dose 1,500 mg daily unless tolerating 2,000 mg well
• Check kidney function before starting and annually

FAQ

How much metformin should I take for weight loss? The evidence-based dose is 1,500 to 2,000 mg daily, divided into two or three doses with meals. Start at 500 mg once daily and increase by 500 mg weekly until reaching the target dose. Doses above 2,000 mg provide no additional weight-loss benefit.

Can I take 500 mg of metformin for weight loss? You can, but 500 mg daily is below the therapeutic dose for weight loss. Clinical trials showing weight loss used 1,500 mg or higher. At 500 mg, you may see improved blood sugar control but minimal weight change. Most patients need at least 1,500 mg daily for measurable weight loss.

Is 1000 mg of metformin enough for weight loss? For most patients, 1,000 mg daily produces minimal weight loss (1 to 2 kg over 6 months). The effective range starts at 1,500 mg. If you're combining metformin with a GLP-1 medication, 1,000 mg may be sufficient as an adjunct. For monotherapy, 1,500 to 2,000 mg is the evidence-based target.

What is the maximum dose of metformin for weight loss? The maximum FDA-approved dose is 2,550 mg daily for immediate-release and 2,000 mg daily for extended-release. For weight loss specifically, doses above 2,000 mg provide no additional benefit and increase side effects. The practical maximum is 2,000 mg daily.

Should I take metformin once or twice a day for weight loss? If using immediate-release, take it twice daily (1,000 mg with breakfast, 1,000 mg with dinner for a 2,000 mg total dose). If using extended-release, take it once daily with dinner. Twice-daily dosing of immediate-release reduces GI side effects compared to taking the full dose at once.

How long does it take for metformin to work for weight loss? Most weight loss occurs in the first 3 to 6 months. You may notice modest changes (2 to 3 lbs) within 4 to 8 weeks at therapeutic doses (1,500+ mg daily). If you see no weight change after 12 weeks at 2,000 mg daily, metformin monotherapy is unlikely to produce significant weight loss for you.

Can I lose weight on metformin without changing my diet? Metformin produces modest weight loss even without intentional diet changes (average 2 to 3 kg in clinical trials where diet was not controlled). However, combining metformin with calorie reduction and increased physical activity produces better results. Metformin is not a substitute for lifestyle modification.

Does metformin extended-release work better for weight loss than immediate-release? No. At equivalent total daily doses, extended-release and immediate-release produce the same weight loss. Extended-release has better GI tolerability (less diarrhea) and allows once-daily dosing, which improves adherence. Better adherence may translate to slightly better real-world outcomes.

Why am I not losing weight on metformin? Three common reasons: (1) dose is too low (below 1,500 mg daily), (2) you don't have insulin resistance (metformin works best in insulin-resistant individuals), or (3) you've been on it long enough (12+ weeks at therapeutic dose) and are a non-responder. About 40% of patients see minimal weight loss on metformin regardless of dose.

Can I take 3000 mg of metformin for weight loss? No. The maximum FDA-approved dose is 2,550 mg daily, and doses above 2,000 mg show no additional weight-loss benefit in any published study. Taking 3,000 mg daily increases diarrhea and GI side effects without improving outcomes and may increase lactic acidosis risk.

Should I take metformin in the morning or at night for weight loss? For immediate-release taken twice daily, take it with breakfast and dinner. For extended-release taken once daily, take it with dinner. Evening dosing of extended-release allows the medication to work overnight when hepatic glucose production is highest, which may improve fasting glucose and insulin sensitivity.

How much weight can I lose on metformin in a month? Expect 1 to 2 lbs per month on average at therapeutic doses (1,500 to 2,000 mg daily). Some patients lose more in the first month (3 to 4 lbs), but the average across clinical trials is modest. Metformin is not a rapid weight-loss medication. Total expected loss over 6 months is 4 to 6 lbs.

Sources

1. Knowler WC et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine. 2002.
2. Diabetes Prevention Program Research Group. Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care. 2012.
3. Yerevanian A et al. Metformin: mechanisms in human obesity and weight loss. Obesity Reviews. 2019.
4. Seifarth C et al. Effectiveness of metformin on weight loss in non-diabetic individuals with obesity. Obesity Reviews. 2013.
5. Levri KM et al. Metformin as treatment for overweight and obese adults: a systematic review. Annals of Family Medicine. 2005.
6. Glueck CJ et al. Metformin, pre-eclampsia, and pregnancy outcomes in women with polycystic ovary syndrome. Fertility and Sterility. 2001.
7. Wulffelé MG et al. Effects of short-term treatment with metformin on serum concentrations of homocysteine, folate and vitamin B12 in type 2 diabetes mellitus. Journal of Internal Medicine. 2004.
8. Blonde L et al. Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets. Diabetes Care. 2004.
9. Garber AJ et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm. Endocrine Practice. 2012.
10. Inzucchi SE et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach. Diabetes Care. 2015.
11. Bailey CJ et al. Metformin: its botanical background. Practical Diabetes International. 2008.
12. Guo Y et al. Efficacy and safety of metformin and liraglutide combination therapy versus monotherapy in obese patients with or at risk for type 2 diabetes. Diabetes Obesity and Metabolism. 2021.
13. Diabetes Prevention Program Outcomes Study Research Group. Long-term effects of metformin on diabetes prevention. Lancet Diabetes and Endocrinology. 2015.
14. American Diabetes Association. Standards of Medical Care in Diabetes - 2022. Diabetes Care. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Metformin is available as generic and under various brand names including Glucophage and Fortamet, which are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any pharmaceutical manufacturers.